Arcutis (ARQT) Q2 Revenue Soars 164%

Arcutis Biotherapeutics (NASDAQ:ARQT), a dermatology-focused pharmaceutical company, reported earnings results on August 6, 2025. Highlights included strong revenue growth and improved earnings, significantly outperforming Wall Street expectations, with GAAP revenue of $81.5 million and GAAP EPS of $0.13, both exceeding analyst estimates. Revenue (GAAP) climbed to $81.5 million, topping analyst forecasts of $73.69 million (GAAP). The company also posted a narrower net loss per share of $(0.13) (GAAP), which came in ahead of estimates by $0.28 (GAAP). This result marks a notable improvement compared to the $(0.42) loss per share (GAAP) in Q2 2024. The quarter demonstrated solid execution in product launches and market expansion, notably for its leading ZORYVE dermatology portfolio. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Arcutis Biotherapeutics is a biopharmaceutical firm dedicated to creating and commercializing treatments for chronic skin conditions. Its primary product family, ZORYVE, features a range of topical therapies: creams and foam based on the phosphodiesterase-4 (PDE4) inhibitor roflumilast. ZORYVE is approved for multiple indications, including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The franchise targets both adult and pediatric markets.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool